Recent advances in selective and targeted drug/gene delivery systems using cell-penetrating peptides.

Authors:
Nam SH; Park J; Koo H.

Journal:
Arch Pharm Res

Publication Year: 2023

DOI:
10.1007/s12272-022-01425-y

PMCID:
PMC9807432

PMID:
36593377

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Arch Pharm Res

Abbreviation: Arch Pharm Res

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Herbal medicine and gut microbiota: exploring untapped therapeutic potential in neurodegenerative d…
Guan Y; Tang G; Li L and 4 more (2024) - Transparency Score: 3/6
Beyond DNA sensing: expanding the role of cGAS/STING in immunity and diseases.
Seok JK; Kim M; Kang HC and 3 more (2023) - Transparency Score: 3/6
Regulation of NOX/p38 MAPK/PPARα pathways and miR-155 expression by boswellic acids reduces hepatic…
Salama RM; Abbas SS; Darwish SF and 3 more (2023) - Transparency Score: 3/6
Targeting dysregulated lipid metabolism in the tumor microenvironment.
Kim DH; Song NY; Yim H. (2023) - Transparency Score: 3/6
Empagliflozin mitigates type 2 diabetes-associated peripheral neuropathy: a glucose-independent eff…
Abdelkader NF; Elbaset MA; Moustafa PE and 1 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflict of interestThe authors declare that they have no conflict of interest. Conflict of interest The authors declare that they have no conflict of interest."

Evidence found in paper:

"This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT, and Future Planning (2021R1A4A3031875, 2022R1A2C1008699), the Korean Fund for Regenerative Medicine (KFRM) grant (21C0702L1) and Korea Health Technology R&D Project (HV22C0069) through the Korea Health Industry Development Institute (KHIDI) funded by the Korea government (the MSIT, the Ministry of Health & Welfare)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025